Valley wants our patients and community to be on the alert against medical billing scams. Learn how to protect yourself and your personal information from scammers posing as hospital representatives.Read More
CytoSorb® Reduction of FREee Hemoglobin/Acute Kidney Injury (AKI) During Cardiac Surgery (REFRESH II Trial)
To study the incidence or severity of acute kidney injury (AKI) in the first 48 hours after cardiopulmonary bypass.
- Experimental: CytoSorb® Device
- Placebo Comparator: Control
- Scheduled for non-emergent cardiac surgery requiring CPB for i) heart valve replacement with any other procedure, without hypothermic circulatory arrest (HCA), or ii) aortic reconstruction with or without another procedure, with HCA